DK0742013T3 - Stabil flydende sammensætning indeholdende uratoxidase samt lyofiliseret sammensætning til fremstilling heraf - Google Patents

Stabil flydende sammensætning indeholdende uratoxidase samt lyofiliseret sammensætning til fremstilling heraf

Info

Publication number
DK0742013T3
DK0742013T3 DK96400995T DK96400995T DK0742013T3 DK 0742013 T3 DK0742013 T3 DK 0742013T3 DK 96400995 T DK96400995 T DK 96400995T DK 96400995 T DK96400995 T DK 96400995T DK 0742013 T3 DK0742013 T3 DK 0742013T3
Authority
DK
Denmark
Prior art keywords
urate oxidase
preparation
stable liquid
composition containing
liquid composition
Prior art date
Application number
DK96400995T
Other languages
Danish (da)
English (en)
Inventor
Claude Aleman
Alain Bayol
Thierry Breul
Patrice Dupin
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Application granted granted Critical
Publication of DK0742013T3 publication Critical patent/DK0742013T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44Oxidoreductases (1)
    • A61K38/443Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK96400995T 1995-05-11 1996-05-09 Stabil flydende sammensætning indeholdende uratoxidase samt lyofiliseret sammensætning til fremstilling heraf DK0742013T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9505606A FR2733914B1 (fr) 1995-05-11 1995-05-11 Composition de liquide stable contenant de l'urate oxydase et composition lyophilisee pour sa preparation
US08/644,163 US5811096A (en) 1995-05-11 1996-05-10 Stable liquid composition containing urate oxidase and lyophilized composition for its preparation

Publications (1)

Publication Number Publication Date
DK0742013T3 true DK0742013T3 (da) 2000-03-06

Family

ID=26231954

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96400995T DK0742013T3 (da) 1995-05-11 1996-05-09 Stabil flydende sammensætning indeholdende uratoxidase samt lyofiliseret sammensætning til fremstilling heraf

Country Status (24)

Country Link
US (1) US5811096A (de)
EP (1) EP0742013B1 (de)
JP (1) JP2950775B2 (de)
CN (1) CN1090972C (de)
AT (1) ATE183925T1 (de)
AU (1) AU710288B2 (de)
BR (1) BR1100337A (de)
CA (1) CA2175971C (de)
CZ (1) CZ290799B6 (de)
DE (1) DE69604009T2 (de)
DK (1) DK0742013T3 (de)
EA (1) EA000024B1 (de)
ES (1) ES2137635T3 (de)
FR (1) FR2733914B1 (de)
GR (1) GR3031896T3 (de)
HU (1) HU225147B1 (de)
IL (1) IL118171A (de)
NO (1) NO315261B1 (de)
NZ (1) NZ286554A (de)
PL (1) PL184135B1 (de)
SG (1) SG42355A1 (de)
SI (1) SI0742013T1 (de)
TW (1) TW420614B (de)
ZA (1) ZA963683B (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030166525A1 (en) * 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
ATE498409T1 (de) 1998-08-06 2011-03-15 Mountain View Pharmaceuticals Peg-uricase konjugate und verwendung davon
US6783965B1 (en) * 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
FR2782455B3 (fr) * 1998-08-20 2000-09-15 Sanofi Sa Composition pharmaceutique injectable a base d'un sel pharmaceutiquement acceptable du clopidogrel ou de ticlopidine
KR101235507B1 (ko) * 2003-02-28 2013-02-20 추가이 세이야쿠 가부시키가이샤 단백질을 함유하는 안정화 제제
DK1610822T4 (en) 2003-04-02 2019-01-14 Ares Trading Sa Liquid pharmaceutical FSH and LH formulations together with a nonionic surfactant
EP1638595B1 (de) * 2003-06-20 2013-03-20 Ares Trading S.A. Gefriergetrocknete fsh / lh formulierungen
US20080159976A1 (en) * 2005-04-11 2008-07-03 Jacob Hartman Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
MX2007012548A (es) 2005-04-11 2008-03-11 Savient Pharmaceuticals Inc Formas variantes de urato oxidasa y uso de las mismas.
US8148123B2 (en) * 2005-04-11 2012-04-03 Savient Pharmaceuticals, Inc. Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
SG161247A1 (en) 2005-04-11 2010-05-27 Savient Pharmaceuticals Inc Variant forms of urate oxidase and use thereof
CN1864744B (zh) * 2005-05-18 2010-09-29 杭州北斗生物技术有限公司 含有尿酸氧化酶的药用制剂
EP1883425A1 (de) * 2005-05-23 2008-02-06 Universite De Geneve Injizierbare superparamagnetische nanoteilchen zur behandlung von hyperthermie und verwendung zur bildung eines hyperthermischen implantats
JP5033177B2 (ja) 2006-04-12 2012-09-26 サビエント ファーマセウティカルズ インク. 陽イオン界面活性剤によるタンパク質の精製
US9377454B2 (en) 2009-06-25 2016-06-28 Crealta Pharmaceuticals Llc Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
CN105412942B (zh) * 2015-12-23 2019-02-26 沈阳三生制药有限责任公司 聚乙二醇化的重组产朊假丝酵母尿酸氧化酶冻干注射剂
EP3443346B1 (de) * 2016-04-13 2023-08-30 Medimmune, LLC Verwendung von aminosäuren als stabilisierende verbindungen in pharmazeutischen zusammensetzungen mit hohen konzentrationen an proteinbasierten therapeutika
CN116637177A (zh) 2016-11-11 2023-08-25 好利恩治疗美国公司 泼尼松和尿酸酶分子的组合疗法及其用途
KR101744900B1 (ko) * 2017-01-20 2017-06-08 주식회사 대웅 보툴리눔 독소를 포함하는 안정한 액상 조성물
WO2020160322A1 (en) 2019-01-30 2020-08-06 Horizon Pharma Rheumatology Llc Tolerization reduces intolerance to pegloticase and prolongs the urate lowering effect (triple)
WO2020160325A1 (en) 2019-01-30 2020-08-06 Horizon Pharma Rheumatology Llc Reducing immunogenicity to pegloticase
US12269875B2 (en) 2023-08-03 2025-04-08 Jeff R. Peterson Gout flare prevention methods using IL-1BETA blockers

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3928137A (en) * 1971-10-20 1975-12-23 Mallinckrodt Inc Reagent formulation for uric acid assay
US3997470A (en) * 1971-10-20 1976-12-14 Mallinckrodt, Inc. Surfactant containing reagent formulations for assaying biological specimens and methods of preparing same
JPS51104807A (en) * 1975-03-12 1976-09-17 Hitachi Ltd Teepurekoodano ootoribaasuseigyokairo
JPS5417027A (en) * 1977-07-07 1979-02-08 Canon Inc Image forming system
DE3126759A1 (de) * 1981-07-07 1983-01-27 Boehringer Mannheim Gmbh, 6800 Mannheim Loesliche leber-uricase, verfahren zu ihrer herstellung und verwendung
JPS60224499A (ja) * 1984-04-23 1985-11-08 Toyobo Co Ltd 安定なウリカ−ゼ製剤
DE3743405A1 (de) * 1987-05-14 1988-11-24 Boehringer Mannheim Gmbh Verfahren zur bestimmung von fructosamin
JPH0243471A (ja) * 1988-08-03 1990-02-14 Iwataro Moriyama 立体駐車装置
JPH06506217A (ja) 1991-03-18 1994-07-14 エンゾン,インコーポレーテッド ポリペプチドまたはグリコポリペプチドとポリマーとのヒドラジン含有結合体
EP0626850B1 (de) 1992-02-18 2002-05-15 Pharmos Corporation Trockene zusammensetzungen zur herstellung von emulsionen im submikron-bereich

Also Published As

Publication number Publication date
BR1100337A (pt) 2000-07-25
AU710288B2 (en) 1999-09-16
TW420614B (en) 2001-02-01
CA2175971A1 (en) 1996-11-12
PL314147A1 (en) 1996-11-12
SI0742013T1 (en) 1999-12-31
EP0742013B1 (de) 1999-09-01
FR2733914A1 (fr) 1996-11-15
US5811096A (en) 1998-09-22
HUP9601241A3 (en) 2000-06-28
ES2137635T3 (es) 1999-12-16
EA000024B1 (ru) 1997-12-30
NO961915D0 (no) 1996-05-10
NO961915L (no) 1996-11-12
CA2175971C (en) 2003-12-30
ZA963683B (en) 1997-11-10
EP0742013A1 (de) 1996-11-13
HU225147B1 (en) 2006-07-28
GR3031896T3 (en) 2000-02-29
IL118171A0 (en) 1996-09-12
EA199600024A2 (ru) 1996-12-30
DE69604009T2 (de) 2000-04-06
ATE183925T1 (de) 1999-09-15
NZ286554A (en) 1998-09-24
CN1090972C (zh) 2002-09-18
JP2950775B2 (ja) 1999-09-20
FR2733914B1 (fr) 1997-08-01
CZ135096A3 (en) 1996-12-11
HU9601241D0 (en) 1996-07-29
MX9601756A (es) 1997-07-31
SG42355A1 (en) 1997-08-15
CZ290799B6 (cs) 2002-10-16
HUP9601241A2 (en) 1997-04-28
IL118171A (en) 2000-08-31
AU5213996A (en) 1996-11-21
JPH0925242A (ja) 1997-01-28
PL184135B1 (pl) 2002-09-30
NO315261B1 (no) 2003-08-11
EA199600024A3 (ru) 1997-03-31
CN1147961A (zh) 1997-04-23
DE69604009D1 (de) 1999-10-07

Similar Documents

Publication Publication Date Title
DK0742013T3 (da) Stabil flydende sammensætning indeholdende uratoxidase samt lyofiliseret sammensætning til fremstilling heraf
DE68919146D1 (de) Ausgewählte Stämme von Lactobacillus enthaltende pharmazeutische Zusammensetzungen.
DE69608896D1 (de) Zubereitungen enthaltend leflunomide
AU1777495A (en) Stable freeze-dried formulation comprising a protein; assay kit
FR2742989B1 (fr) Composition pharmaceutique bioadhesive pour la liberation controlee de principes actifs
GR3033204T3 (en) Formulations of blood clot-polymer matrix for delivery of osteogenic proteins.
AU681452B2 (en) Pernasal composition and pernasal preparation containing thesame
EP1013274A3 (de) Zubereitung enthaltend Amoxycillin und Clavulansäure
ITMI911580A1 (it) Preparazioni oftalmiche a rilascio protratto
IT1264856B1 (it) Composizione farmaceutica ad attivita' analgesica